Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Wilms Tumor 9Prostatic Neoplasms 9Glioma 9Osteosarcoma 8Neuroblastoma 8Multiple Myeloma 8Leukemia, Myeloid, Acute 8Sarcoma 7Rhabdoid Tumor 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Carcinoma, Hepatocellular 5Sarcoma, Ewing 4Ovarian Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3

Interventions

cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non functioning pancreatic endocrine tumor × X-Rays × 90 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡